The Application dimension of Peptide Microarray Service segmentation distinguishes five primary use‑cases. Immunology accounts for the largest share, driven by antibody‑profiling studies, vaccine candidate screening, and autoimmune‑disorder diagnostics; these activities generate the highest service‑hour demand and thus dominate market revenue. Oncology follows, where peptide arrays enable tumor‑associated antigen discovery, neo‑epitope validation, and immunotherapy target verification, contributing a substantial portion of contracts with pharmaceutical firms. Infectious‑disease applications focus on pathogen‑epitope mapping, serological surveillance, and antimicrobial‑vaccine development, supporting both public‑health agencies and biotech startups. Neurology encompasses research on neuro‑autoimmune conditions such as multiple sclerosis, where epitope‑specific antibody detection informs therapeutic strategies. The residual Other category aggregates niche uses—food‑safety allergen detection, environmental toxin screening, and basic research—each adding incremental revenue. Revenue contribution aligns with R&D spending trends; immunology benefits from rising biologics pipelines, oncology from checkpoint‑inhibitor programs, infectious disease from pandemic preparedness, neurology from increasing prevalence of autoimmune neuropathies. Collectively, these five application segments shape the overall market size, with their relative weights reflected in the accompanying pie‑chart. This analysis underscores the relevance of Peptide Microarray Service segmentation for strategic planning.